VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on VolitionRx (VNRX) to $1.50 from $2.50 and keeps a Buy rating on the shares. VolitionRx posted Q3 revenue that was up 32% year over year and a $5.4M net loss, while securing two notable human diagnostics agreements with Werfen and Hologic (HOLX), the analyst tells investors in a research note. With roughly 10 major diagnostics and liquid-biopsy companies engaged at various stages of partnership discussions, management expects additional licensing deals, underscoring the broad potential of the Nu.Q platform across cancer, sepsis, and epigenetic drug development, the firm says.